{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:14:46Z","timestamp":1793420086744,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010002","name":"Executive Yuan Republic of China Ministry of Education","doi-asserted-by":"publisher","award":["#NTU-112L9004"],"award-info":[{"award-number":["#NTU-112L9004"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["#NSC-112-2314-B-002-216-MY3"],"award-info":[{"award-number":["#NSC-112-2314-B-002-216-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jmii.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:48:55Z","timestamp":1752608935000},"page":"152-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of the monovalent XBB.1.5 COVID-19 vaccines: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-0584","authenticated-orcid":false,"given":"Hsin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8187-373X","authenticated-orcid":false,"given":"Yi-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Liang","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-1949","authenticated-orcid":false,"given":"Yu-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-0232","authenticated-orcid":false,"given":"Tzeng-Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-1699","authenticated-orcid":false,"given":"Chi-Tai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jmii.2025.07.002_bib3","first-page":"S0929","article-title":"Impact of pre-Omicron COVID-19 vaccine boosters on the risk of Omicron variant infections: a systematic review and meta-regression","author":"Pan","year":"2025","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"10.1016\/j.jmii.2025.07.002_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(23)00051-8","article-title":"Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant","volume":"23","author":"Uriu","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"42","key":"10.1016\/j.jmii.2025.07.002_bib6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.15585\/mmwr.mm7242e1","article-title":"Use of updated COVID-19 vaccines 2023-2024 formula for persons aged \u22656 months: recommendations of the advisory committee on immunization practices - United States, september 2023","volume":"72","author":"Regan","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.jmii.2025.07.002_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.jmii.2025.07.002_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamainternmed.2024.1637","article-title":"Evaluating COVID-19 vaccines in the era of endemicity-recency vs reformulation","volume":"184","author":"Mohan","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jmii.2025.07.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102102","article-title":"Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study","volume":"62","author":"Qassim","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.jmii.2025.07.002_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2024-001074","article-title":"Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data","volume":"3","author":"Andersson","year":"2024","journal-title":"BMJ Med"},{"issue":"8","key":"10.1016\/j.jmii.2025.07.002_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13360","article-title":"Early COVID-19 XBB.1.5 vaccine effectiveness against hospitalisation among adults targeted for vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024","volume":"18","author":"Antunes","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib15","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","article-title":"Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare system","volume":"15","author":"Caffrey","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jmii.2025.07.002_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.15585\/mmwr.mm7308a5","volume":"73","author":"DeCuir","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"10.1016\/j.jmii.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.vaccine.2024.05.067","article-title":"Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024","volume":"42","author":"Laniece","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jmii.2025.07.002_bib18","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1473-3099(23)00746-6","article-title":"Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study","volume":"24","author":"Hansen","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2025.07.002_bib19","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109","article-title":"Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, The Netherlands, October 2023 to January 2024","volume":"29","author":"Huiberts","year":"2024","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106177","article-title":"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","volume":"89","author":"Kirsebom","year":"2024","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.jmii.2025.07.002_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106293","article-title":"Protection of vaccine boosters and prior infection against mild\/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: october 2023 to March 2024","volume":"89","author":"Kirwan","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2025.07.002_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107249","article-title":"Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - october 26 to December 31, 2023","volume":"148","author":"Lee","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"22","key":"10.1016\/j.jmii.2025.07.002_bib23","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMc2402779","article-title":"Durability of XBB.1.5 vaccines against Omicron subvariants","volume":"390","author":"Lin","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2025.07.002_bib24","doi-asserted-by":"crossref","unstructured":"Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, et al. Effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 omicron xbb and ba.2.86\/jn.1 lineage Hospitalization and a comparison of clinical severity-IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024. Clin Infect Dis. Published online August 6, 2024.","DOI":"10.1093\/cid\/ciae405"},{"issue":"11","key":"10.1016\/j.jmii.2025.07.002_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70009","article-title":"Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in older adults during the JN.1 lineage-predominant period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024","volume":"18","author":"Merdrignac","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"10.1016\/j.jmii.2025.07.002_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13292","article-title":"Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU\/EEA countries, october to november 2023: a VEBIS-EHR network study","volume":"18","author":"Monge","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.jmii.2025.07.002_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1382944","article-title":"Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis","volume":"15","author":"Nham","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib28","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2024.2428800","article-title":"Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86\/JN.1 period among older adults in seven European countries: a VEBIS-EHR network study","volume":"23","author":"Nunes","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.jmii.2025.07.002_bib29","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.7.2400076","article-title":"2023\/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)","volume":"29","author":"Skowronski","year":"2024","journal-title":"Euro Surveill"},{"issue":"8","key":"10.1016\/j.jmii.2025.07.002_bib30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamainternmed.2024.1640","article-title":"Estimated effectiveness of the BNT162b2 XBB vaccine against COVID-19","volume":"184","author":"Tartof","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.jmii.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"ofae370","DOI":"10.1093\/ofid\/ofae370","article-title":"Effectiveness of BNT162b2 XBB vaccine against XBB and JN.1 sublineages","volume":"11","author":"Tartof","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib32","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.1.2300703","article-title":"Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, The Netherlands, 9 October to 5 December 2023","volume":"29","author":"van Werkhoven","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jmii.2025.07.002_bib34","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jmii.2025.07.002_bib35","author":"Wells"},{"issue":"5","key":"10.1016\/j.jmii.2025.07.002_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"Wu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jmii.2025.07.002_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"issue":"7414","key":"10.1016\/j.jmii.2025.07.002_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jmii.2025.07.002_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"7650","key":"10.1016\/j.jmii.2025.07.002_bib40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.jmii.2025.07.002_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"49","key":"10.1016\/j.jmii.2025.07.002_bib44","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.15585\/mmwr.mm6949e2","article-title":"Summary of guidance for public health strategies to address high levels of community transmission of SARS-CoV-2 and related deaths, December 2020","volume":"69","author":"Honein","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jmii.2025.07.002_bib45","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","article-title":"Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024","volume":"73","author":"Roper","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.jmii.2025.07.002_bib46","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jmii.2025.07.002_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jmii.2025.07.002_bib48","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/vaccines10122180","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): a systematic review with meta-analysis and meta-regression","volume":"10","author":"Pratama","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.jmii.2025.07.002_bib49","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.jmii.2025.07.002_bib51","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jmii.2025.07.002_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","article-title":"Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged \u226518 years - VISION and IVY networks, September 2024-January 2025","volume":"74","author":"Link-Gelles","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10328","key":"10.1016\/j.jmii.2025.07.002_bib53","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jmii.2025.07.002_bib54","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/cid\/ciz706","article-title":"Depletion-of-susceptibles bias in analyses of intra-season waning of influenza vaccine effectiveness","volume":"70","author":"Ray","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jmii.2025.07.002_bib55","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/aje\/kwac015","article-title":"Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines","volume":"191","author":"Kahn","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jmii.2025.07.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111223","article-title":"Expression of SARS-CoV-2 spike protein in cerebral arteries: implications for hemorrhagic stroke post-mRNA vaccination","volume":"136","author":"Ota","year":"2025","journal-title":"J Clin Neurosci"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:34:10Z","timestamp":1777620850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1684118225001379"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.07.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of the monovalent XBB.1.5 COVID-19 vaccines: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}